Plotting 1/EC50 values versus HER3 expression revealed a strong increase in potency for the scDb-scFv molecule above approximately 9000 HER3 molecules/cell, which was not seen for scDb, indicating an avidity-mediated gain in target cell killing for cancer cells expressing medium levels of HER3 (Fig. 4j). The gene discussed is ERBB3; the disease is cancer.